Rohan Dharmakumar
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rohan Dharmakumar sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Rohan Dharmakumar: 8 sponsored US clinical trials, 1 recruiting.
Rohan Dharmakumar sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myocardial Infarction Type 1, with 1 trials.
Upper-quartile sponsor footprint
Rohan Dharmakumar sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
NCT05604131
National Landscape of Hemorrhagic Myocardial Infarction in the United States
NCT06162039
Hemorrhagic MI Prediction Score Model
NCT06423625
Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes
NCT06851325
Acute MI Staging Diagnosis by High-sensitivity Cardiac Troponin-I
NCT07163988
Hemorrhagic Myocardial Infarction Detection by Post-reperfusion Troponin Kinetics
NCT05872308
Novel Imaging Biomarkers for Mechanical Complications in Acute Myocardial Infarction
NCT06450912
Arrhythmias in Hemorrhagic Myocardial Infarction During the Acute Post-PCI Phase
NCT06611384
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Rohan Dharmakumar pipeline
1 recruiting of 8 indexed (13% open); 7 completed (88%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Acute Myocardial Infarction Type 1 (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rohan Dharmakumar: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Rohan Dharmakumar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this Rohan Dharmakumar page
8 registered trials is a research-attention snapshot, not an endorsement of Rohan Dharmakumar or any single study.
- 1 of Rohan Dharmakumar's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myocardial Infarction Type 1 is the condition Rohan Dharmakumar studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myocardial Infarction Type 1 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Rohan Dharmakumar pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.